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STATISTICAL METHODS FOR ASSESSING TREATMENT EFFECTS 
FOR OBSERVATIONAL STUDIES 
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Though randomized clinical (RCTs) trials are the gold standard for comparing 
treatments, they are often infeasible or exclude clinically important subjects, or generally 
represent an idealized medical setting rather than real practice.  Observational data provide 
an opportunity to study practice-based evidence, but also present challenges for analysis.  
Traditional statistical methods which are suitable for RCTs may be inadequate for the 
observational studies.  In this project, four of the most popular statistical methods for 
observational studies: ANCOVA, propensity score matching, regression with the propensity 
score as a covariate, and instrumental variables (IV) are investigated through application to 
MarketScan insurance claims data.  Each of these methods is used to compare BMP versus 
autograft spinal surgeries for the outcomes length of stay, complications, and cost.  
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When there are multiple treatment methods for a common condition, it is natural to 
want to compare the treatments directly.  Undoubtedly, the best way to accomplish this is 
through randomized clinical trials (RCTs).  However, the costs can be prohibitive – in money, 
time, the availability of applicable participants, etc. – which has led researchers to turn to 
alternatives to RCTs, one of most common of which is comparative effectiveness research 
(CER).  CER has been defined by the Institute of Medicine committee as “the generation and 
synthesis of evidence that compares the benefits and harms of alternative methods to 
prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care.  
The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make 
informed decisions that will improve health care at both the individual and population 
levels”[1, 2, 3].  CER requires the development, expansion, and use of a variety of data sources 
and methods to conduct timely and relevant research and disseminate the results in a form 
that is quickly usable by clinicians, patients, policy makers, and health plans and other 
payers[4].  The data sources could be observational data (e.g. administrative claims data, 
electronic medical records, registries, or other clinical cohorts) or randomized clinical 
trials[5]. 
RCTs are the most rigorous method of generating comparative effectiveness 
evidence and are considered the gold standard for evaluating the efficacy of a treatment.  
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RCTs incorporate randomization of test subjects: an essential component to many of the 
assumptions underlying traditional statistical analyses.  When subjects are randomly 
assigned to two treatment groups, and when the sample size is large, the two treatment 
groups are balanced on all potential covariates, both observed and unobserved.  This means 
that there are not fundamental underlying differences between the two treatment groups 
that are causing differences in treatment response, and the observed difference in response 
is instead due only to the treatment assignment.  Randomization is the only way to 
effectively achieve balance of both observed and unobserved covariates between 
treatment groups.  Traditional methods of analysis for RCTs, such as Student t-tests, or the 
Wilcoxon-Manny test if the outcome variable is not normally distributed, are well studied 
and well understood. 
However, many RCTs exclude clinically relevant patient subgroups (as defined by 
age, sex, race, ethnicity, and comorbid conditions), commonly used comparator 
interventions, important patient outcomes (such as quality of life and longer-term effects), 
and non-expert providers.  These exclusions diminish the relevance of the trial results for 
some important clinical and policy decisions[5].  On the other hand, the observational data, 
such as administrative claims, electronic medical records, and registries, provide 
opportunities to study the practice-based evidence[6].  Unlike with RCTs, the potential 
covariates (both observed and unobserved) could be unbalanced between treatment 
groups, or could even contain no overlap at all.  Thus, any observed difference in outcomes 
between the groups could be the result of the treatments, or it could be the result of 
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differing covariate measures.  To make valid estimates of the treatment effect, appropriate 
statistical methods must be used to adjust for the potential imbalance in the  
covariates[7, 8].  In this project, it is my aim to examine four of the most popular statistical 
methods used in observational studies: the standard analysis of covariance (ANCOVA) 
approach, the propensity score-based regression method, the propensity score-based 
matching method, and the use of instrumental variables (IV).  Each method has its own 
assumptions and is applicable under certain settings.  I wish to highlight the pros and cons 
of each method, compare these methods via data analyses on MarketScan administrative 
claims data, and provide guidelines for which method may be optimal for a given CER study. 
Without loss of generality, let us assume we are interested in comparing the 
outcome between a treatment group and a control group.  The treatment effect, 
conceptually, is the difference in outcome a subject experiences when given treatment 
versus that he experiences given control.  The two most common measures of treatment 
effect are population average treatment effect (ATE) and average treatment effect among 
the treated (ATT).  To describe the treatment effect rigorously, I borrow the “potential 
outcome” notation used by Rosenbaum and Rubin[9], Rubin[8], Little and Rubin[10], and 
Hirano, Imbens, and Ridder[11].  Suppose a random sample of size N subjects, indexed by 
i=1,…,N, are drawn randomly from a large population.  The ith subject has the outcome   (1) 
if the subject receives the treatment, and has the outcome   (0) if the subject receives the 
control.    (0) and    (1) are called the “potential outcomes” for i
th subject, where either 
  (1) or   (0), depending on the treatment the subject received, is observed.  In addition, 
each subject has a vector of characteristics, referred to as covariates or pre-treatment 
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variables, denoted by      Rubin
[8] called the covariates and the potential outcomes, say 
(     ( )   ( )), the science, which is not affected by how or whether we try to learn 
about it, whether by completely randomized experiment, randomized blocks designs, or 
observational studies.  The treatment effect for ith subject would be defined as  
     [  ( )    ( )]  (1) 
The population average treatment effect (ATE) is defined as: 
       [ ( )   ( )]  (2) 
where  ( ) denotes expectation in the population.  Let    denote the treatment assignment 
for ith subject (i=1,…,N),    = 1 if the subject receives treatment, and     = 0 if the subject 
receives control.  The average treatment effect among the treated (ATT) is defined as 
       [ ( )   ( )|   ]  (3) 
The expression for ATE and ATT are very straightforward theoretically, but in 
practice it is impossible to observe both   (1) and   (0) for the same subject.  When subjects 
are randomly assigned to treatment and control groups, the treatment assignment is 
independent of the outcome variables, which implies that ATT and ATE are equal.  However, 
in observational studies, ATT may be greater than ATE, if for example, people who elect 
treatment do so because they are more likely to benefit from the treatment than those who 
elect not to receive treatment.  This is known as selection bias, and in medical settings, it is 
probably reasonable to assume that selection bias is taking place, since a doctor would 
reasonably be expected to recommend a procedure to a patient if he thinks that patient is a 
particularly good candidate for the procedure and will respond well.  Conversely, the doctor 
may not recommend the procedure to a lesser candidate, since the benefit may not be 
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worth the cost.  Thus, in observational studies from medical settings, it is likely that the ATT 
will be greater than the ATE, because the treatment group is comprised of a greater 
proportion of “ideal” candidates than is found in the general population.   
Although the definition for ATE and ATT are straightforward, it is impossible to 
estimate these quantities without making speculations about the outcome one treatment 
would have had on a subject which, in fact, did not receive such treatment.  Using the 
notation of Angrist and Pischke[12], in general, the average treatment effect is estimated by 
 ( ( )|     )   ( ( )|     )   Note that 
     ( ( )|     )   ( ( )|     )  
   {( ( )   ( ))|     }   ( ( )|     )   ( ( )|     )  (4) 
 ( ( )|     )   ( ( )|     ) could be estimated by the observed difference of 
outcomes in treated group and control group, the first term in the right hand of Equation 
(4),  {( ( )   ( )|     }, is the average treatment effect on the treated, and the 
second term in the right hand of Equation (4),  ( ( )|     )   ( ( )|     ), is the 
selection bias, describing the outcome difference and the treatment group and the control 
group if the treatment group had received the control.  In the case that there is not 
selection bias, the observed difference of outcomes between treated group and control 
group is an unbiased estimate for ATT[12].  In RCTs, the potential outcomes, say ( ( )  ( )), 
are independent of the treatment assignment, thus the selection bias is zero.  For non-
randomized studies, Rosenbaum and Rubin[9] coined the “ignorable treatment assignment” 
assumption: 
 ( ( )  ( ))  |    (5) 
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This assumption says that the treatment assignment is independent of the potential 
outcome variables ( ( )  ( )).  This assumption is also referred to as the 
“unconfoundedness assumption” according to Imbens[13], and the “conditional 
independence assumption”[12].  Under this assumption, the selection bias is zero, and 
 {( ( )   ( ))|     }   {( ( )   ( ))| }  
which implies that the ATT and ATE are the same. The “overlap” assumption[13], regarding 
the joint distribution of treatments and covariates, says that 
      (   | )     (6) 
Under the “overlap” assumption, for a given covariate    , there are some subjects 
assigned to treatment group, and there are some subjects assigned to control group.  The 
“overlap” assumption and the “unconfoundedness assumption”[13] altogether are referred 
to as “strongly ignorable treatment assignment” assumption as expressed by Rosenbaum 
and Rubin[9], which are the key assumptions for valid inferences for treatment effect based 
on the ANCOVA approach or the propensity score-based regression/matching methods.  
Analysis of covariance (ANCOVA) is the fundamental method of analysis in both 
randomized and non-randomized studies – including CER – as it is possible to pair with 
propensity score analysis and is the necessary underpinning for IV analysis, or ANCOVA can 
stand alone as the method of analysis in an observational study.  ANCOVA is very well 
established, dating back to Fisher’s use in a 1932 study[14].  The method is valued for its ease 
of implementation, straightforward interpretation, and widespread understanding of its 
applications, qualities, and drawbacks.  However, when there are a large number of 
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covariates, one may run into the high-dimensional problem.  In such cases, the propensity 
score based methods can easily address the high-dimensional issue.   
The propensity score is defined as the conditional probability of assignment to 
treatment group, given the covariates, 
   ( )    (   |   ). (8) 
Rosenbaum and Rubin[9] showed that under the “strongly ignorable treatment assignment” 
assumption, the difference between treatment and control means at each propensity score 
is an unbiased estimate of the treatment effect at that value, and consequently pair 
matching, subclassification and covariance adjustment on the propensity score can produce 
unbiased estimates of the average treatment effect.  Propensity scores contain information 
about all observed covariates, and propensity scores have become a very popular way to 
balance covariates between treatment groups in observational studies, and thus produce 
unbiased estimates of the treatment effects.  In addition, the propensity score can be used 
in a model as a replacement for a vector of all the individual background covariates[16].  
When there are a very large number of covariates, this can greatly simplify the model and 
avoid the high dimensionality problems.  Either alone or with select covariates, the simpler 
model using propensity score rather than all covariates may allow for more reliable 
goodness-of-fit tests on the model[16].  Additionally, there is no concern with over-
parameterization of the model when using propensity scores, as there is with a regression 
using all covariates individually[16].  While the propensity score can stand alone, it can also 
be combined with a vector of what are deemed the most important or influential covariates 
in a regression model.   
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While propensity score analysis can be very effective in eliminating bias due to 
imbalance in measured covariates, there could be significant confounding due to imbalance 
in unmeasured or unobserved covariates, which may make the “unconfoundedness” and 
“overlap” assumptions invalid.  In these cases, instrumental variables (IV) for treatment 
assignment – if they can be found – may be applied to deal with this confounding and 
reduce the bias of estimates of the treatment effect.  The instrumental variable Z (if one 
exists) should be one that is correlated with the treatment assignment variable but 
uncorrelated with the error term.  A two-stage least squares (2SLS or TSLS) method is then 
generally applied to estimate the treatment effect.  The first stage involves regressing the 
instrument onto the treatment X, resulting in an estimate of  ̂ by OLS.  Then  ̂ is regressed 
onto the outcome variable Y in the second stage, yielding an unbiased estimate of the 
treatment effect. 
I will apply the ANCOVA method, the propensity score method, and the instrumental 
variables method to compare “the effectiveness and the cost-effectiveness of two relatively 
new highly popular spinal technologies: BMP [bone morphogenetic proteins] vs. autograft 
for spinal fusion for degenerative disease” using the MarketScan insurance claims dataset, 
which is a database of Medicare, Medicaid, and commercial insurance claims over the years 
2004-2009.  The outcome variables are length of hospital stay, complications, in-hospital 









ANALYSIS OF COVARIANCE 
Analysis of covariance (ANCOVA) is a fundamental statistical method of analysis for 
both randomized and nonrandomized studies.  It is a regression analysis which includes 
parameter estimates for observed covariates in addition to the treatment effects we are 
ultimately interested in estimating.  ANCOVA for two treatment groups can be written as 
          (     ̅)     . (9) 
   is the outcome measure for the ith subject, µ is the mean for the control group,   is the 
average difference between the treatment group and the control group,    is a 
measurement of the observed covariates for each experimental unit, with  ̅  
 
 
∑   
 
   ,    
is the treatment indicator variable, and    is the error term, which is usually assumed to 
follow a normal distribution with mean zero and variance σ2.    is a parameter that removes 
the influence of the measured covariates from the error term.  It is assumed in this model 
that the covariates properly influence    in a linear fashion
[15].  By including a measure of 
the covariate in the regression, confounding is reduced and more precise estimates of the 
true treatment effects are obtained, even where randomization was employed[15].  Of 
course, where randomization is not employed, as is the case with observational studies, 




As stated, ANCOVA may be used to improve the precision of estimates of the 
treatment effect in randomized experiments.  This works because randomization does not 
ensure complete balance of covariates between treatment groups, and if measurements of 
observed covariates are taken before treatment, ANCOVA will adjust for any imbalance of 
the observed covariates.  Randomization is still useful because it is the only way to balance 
unobserved covariates.  According to Cochran, the improvement in precision “depends 
primarily on the size of the correlation coefficient ρ between y and x on experimental units 
that receive the same treatment”[15].  The actual value of the gain is approximately given by 
 
  
 (     ) {   
 
    
} (10) 
where   
  is the observed error variance when ANCOVA is not used,    is the error degrees 
of freedom, and ρ is the correlation between x and y.   
For nonrandomized experiments, ANCOVA is used to remove bias caused by 
imbalance in covariates.  However, there are underlying assumptions for ANCOVA which 
should be met in order to draw valid statistical inference.  The underlying assumptions are 
that (1) the treatment and regression effects must be additive, (2) the residuals must be 
independent and identically distributed following a normal distribution with mean zero, and 
(3) that the researcher specify the correct regression relationship, i.e., that the true 
relationship be linear, that it be quadratic, etc.[15] if it is specified as such in the model.  
Culpepper and Aguinis[17] note another assumption which is that (4) the covariate 
measurements must be taken without error.  If there are measurement errors on a 
covariate, this covariate is referred to as a fallible covariate.  The presence of fallible 
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covariates may cause a number of problems.  Model diagnostics should be checked to 
ensure that these assumptions are not violated. 
The ANCOVA method does have drawbacks.  The primary drawback is that ANCOVA 
can do nothing to assuage the problems of unmeasured covariates.  Randomization may 
balance unmeasured covariates so that the inference based on ANCOVA will still be valid.  
However, for nonrandomized studies unmeasured covariates may not be balanced.  Strong 
theoretical expertise of the researcher guiding a study may allow for the identification of 
important potential unmeasured covariates. 
A second drawback arises when different treatment groups have, as a whole, very 
different values of the measured covariates.  In this case, the regression equation involves 
some degree of extrapolation in the range of covariate values between the various groups.  
This is problematic because the regression may not appropriately model this region which 
was unpopulated or sparsely populated in the study sample.  The efficiency of the test of 
the difference in the estimated treatment effects suffers regardless[15]. 
A third drawback results from the use of fallible covariates.  Fallible covariates don’t 
present difficulties simply in decision making.  Culpepper and Aguinis state that “controlling 
for fallible covariates leads to biased treatment effects,” and that the presence of fallible 
covariates can greatly inflate Type I error rates[17].  They studied three techniques for 
handling fallible covariates in addition to OLS when fallible covariates are present: the 
errors-in-variables (EIV) method, Lord’s method, and Raaijmakers and Pieter’s (R&P) 
method.  The greatest bias was produced when naïvely proceeding with ANCOVA despite 
knowledge of fallible covariates, suggesting that if fallible covariates are known or 
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suspected, a researcher should not proceed with the ANCOVA method.  In short, they 
determined that the EIV method is optimal among these choices based on an investigation 
of Type I error rates, statistical power, and estimate bias[17]. 
ANCOVA has become a ubiquitous method of statistical control and analysis because 
its implementation is straightforward and simple and it is comparatively easy to interpret 
the results.  And when the assumptions are met, it is an effective tool for reducing bias due 
to measured confounders.  But the drawbacks highlight the need to rely on some 








CHAPTER III  
 
PROPENSITY SCORE METHODS 
The use of propensity scores has become popular in observational studies.  
According to Austin[18], the propensity score exists for all studies, whether they are 
randomized or merely observational.  The true propensity score is known in a randomized 
trial; however, it is not known in observational studies and must be estimated from the 
data.  Recall that the propensity score is defined as the conditional probability of an 
individual receiving treatment given that individual’s observed covariates, that is 
  ( )     (   |   ) (11) 
The propensity scores can be estimated using logistic regression of the following form, as 
indicated by D’Agostino and Austin[16, 18]: 
 
   
 ( )
   ( )
    
  (   |   )
    (   |   )
                       (12) 
Since a subject is in either the treatment group or the control group, we obtain the 
estimated parameters   and   based on the treatment received and the subject’s 
covariates, and we obtain a propensity score for each subject.  We can then use the 
propensity score in different ways to obtain a valid estimate for the treatment effect.  In 
this section, I outline four popular propensity score based methods: (1) matching based on 
the propensity score, (2) regression using propensity score as a covariate, (3) stratification 
based on the propensity score, and (4) inverse probability of treatment weighting (IPTW).   
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3.1 Matching methods 
Matching is a technique for statistical analysis in which subjects from different 
exposure groups are paired together.  Each pair is then treated as though it represents a 
single trial of the experiment or comparison in question.  Subjects can be paired one-to-
one, one-to-many, or many-to-many, and with or without replacement.  Typically, subjects 
who are the closest matches for each other based on their covariates are paired, which is 
known as greedy matching, and each subject is removed from consideration for future 
pairings, which is matching without replacement.  If a single subject is used in multiple 
pairings, this is matching with replacement.  Another method is optimal matching, in which 
the total distance between covariate values for all matched pairs is minimized.   
Greedy matching without replacement:  The simplest technique is to match cases 
with the nearest available control based simply on the propensity score.  Once a subject has 
been matched, he is removed from consideration for future matches.  This is greedy 
matching without replacement based on the propensity score. 
Mahalanobis metric matching:  A more complex method is Mahalanobis metric 
matching including the logit of the estimated propensity score as a covariate.  Mahalanobis 
matching involves calculating the distance between a case and all the controls by the 
following formula: 
  (   )  (   )    (   ) (13) 
where d(i, j) is the distance between case i and control subject j, u and v are the values of 
the variables they are being matched on, and C is the sample covariance matrix of the 
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matching variables from the full set of controls[16].  Again, once a case has been matched to 
the nearest control, both are removed from consideration for future matches. 
Mahalanobis metric matching within calipers:  A third matching method is 
Mahalanobis metric matching within calipers based on the propensity score.  The first step 
is to identify which control subjects are within a predetermined difference in the estimated 
propensity score (the caliper width) from the case to be matched.  Mahalanobis distances 
from the case subject are then calculated for each of these potential control matches, the 
nearest neighbor is matched, and the two are removed from consideration for future 
matches.  The caliper size can be determined by the investigator, though Rosenbaum and 
Rubin advise using a caliper that is “a quarter of a standard deviation of the logit of the 
propensity score.”[9, 16]  Austin suggests that the optimal caliper width (if variance of the 
logit of the propensity score is the same in treated and control groups) is a fifth of the 
standard deviation, and that this caliper width will eliminate 99% of the bias due to 
measured covariates[18]. 
Kernel Matching:  A fourth matching method, known as Kernel Matching, is 
described by Becker and Ichino[19].  Succinctly, all treated subjects are matched to a 
weighted average of all the control subjects where the weights are inversely proportional to 
the distance between the propensity score estimates for the treated versus control 
subjects.  The estimator (of average treatment effect among the treated) based on kernel 
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 (14) 
where T is the set of treated subjects, C is the set of control subjects, ei and ej are the 
propensity scores for treatment subject i and control subject j,   
  and   
  are the observed 
outcomes for treatment subject i and control subject j,  is the number of subjects in the 
treated group,    is a bandwidth parameter, and G(∙) is a kernel function. 
There is some disagreement about how the variance, and thus the analysis, of 
matched pair designs should be handled.  Austin[18] argues that while some researchers 
believe matched pairs can be treated as independent observations, he does not believe this 
is a good approach for propensity score matched samples.  His reasoning is that since 
matched pairs have similar values of the propensity score (by definition), their covariates 
come from the same distribution, and baseline covariates are also related to outcomes.  
Austin argues for the use of a paired t-test to analyze continuous outcome data or 
McNemar’s test to analyze dichotomous outcome data[18].   
3.2 Stratification methods 
Stratification is in some sense a generalization of matching methods.  Instead of 
cases and controls being matched directly, strata – defined by the covariates to match on – 
are populated by all subjects, both cases and controls, who happen to fall within each 
stratum based on the values of their covariates.  The number of strata can depend on 
factors such as the total sample size, whether the cases and controls tend to cluster around 
specific values of covariates or not, or attempting to balance the number of subjects in each 
stratum while ensuring that those subjects are also as similar as possible in their covariate 
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balance.  We consider stratification as a generalization of matching because using the 
maximum possible number of strata (which contain both a case and a control) would 
essentially result in matched pairs – each pair being its own stratum.  For any stratification 
scheme, the investigator must determine how he wants to determine the stratification 
boundaries – whether they will be based on the estimated propensity scores for only the 
cases, for only the controls, or for the combined group of cases and controls[16]. 
Stratification methods may still suffer the same problems as matching, namely that a 
large number of covariates will make it very difficult to find both cases and controls that will 
fall into the same strata, since the number of strata will grow exponentially with the 
number of covariates[16].  However, Rosenbaum and Rubin showed that the propensity 
score is a balancing score, and it contains information about all the observed covariates that 
need to be balanced.  Thus, stratification based on the propensity score is straightforward 
and does not suffer from the high dimensionality problem mentioned above.  Rosenbaum 
and Rubin contend that stratification on the propensity score effectively balances all 
covariates that are used to estimate it, and that using five strata is often sufficient to 
remove over 90% of the bias in the covariates[9, 16]. 
3.3 Regression models using the propensity score 
To explain how propensity scores are useful in a regression adjustment (aka 
covariance adjustment), consider a regression model of the estimation of the treatment 
effect τ as described by D’Agostino[16]. 





Y represents the response variable.  The first term on the right hand side of the equation 
represents the average treatment effect absent any influence from the covariates, that is, 
the average difference in response between the treated and control groups.    is the 
regression estimate of the responses of the two groups on the covariates.  The propensity 
score makes this estimation much simpler because, again, the propensity score is a single 
variable whereas the set of covariates for each group would likely otherwise be a vector 
with many variables. 
A second method for regression adjustment is to include the propensity score 
estimates along with a small subset of the most important covariates in the regression 
model.  D’Agostino claims that this method is analogous to the Mahalanobis metric 
matching method within calipers discussed previously.  D’Agostino also warns against using 
regression adjustment if the variance in the treated group is very different than the variance 
in the control group, and that it’s probably best to consider other methods under this 
scenario[2]. 
Regression techniques must be approached with caution, since an underlying 
relationship between explanatory variables and response must be assumed, and departures 
from the assumed relationship can lead to biased results.  
3.4 Inverse Probability of Treatment Weighting (IPTW) 
IPTW “uses weights based on the estimated propensity score to create a synthetic 
sample in which the distribution of measured baseline covariates is independent of 
treatment assignment.  The use of IPTW is similar to the use of survey sampling weights 
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that are used to weight survey samples so that they are representative of specific 
populations.”[18]  The weights are defined as follows: 
 




(     )
     
 (16) 
where Ti is an indicator variable for treatment versus control for subject i, and ei is the 
propensity score for subject i.  This weight is equal to the inverse of the probability of 
receiving the treatment that the subject actually received.  If a subject has a very low 
probability of receiving the treatment he actually received, then the weights may be 
inaccurate, and a few proposed solutions are mentioned by Austin[18]. 
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 (17) 
where Yi is the outcome variable measure for subject i, and n is the number of  
subjects[18, 20]. 
A comparison of these four propensity score methods was conducted by Austin[18], 
who concluded that IPTW was essentially equal or inferior to propensity score matching 
methods.  Also, he notes that IPTW and regression adjustment may be more sensitive to 
whether the propensity score has been accurately estimated as compared to matching or 
stratification[18].  Numerous studies have shown that stratification on the propensity score is 
inferior to matching, and since “increasing the number of strata used should result in 
improved bias reduction,”[18] it makes sense that stratification will not perform as well as 
matching, which essentially creates as many strata as are possible from the data by virtue of 
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each matched-pair being its own comparison stratum.  Additionally, Lunceford and Davidian 
showed that the stratification method produces more biased estimates than other 
methods, and that this bias actually increases with sample size[18, 20].  Becker and Ichino note 
that, in use on their data set, stratification gave slightly different results than matching 
techniques, though overall, results were close for all propensity score methods they 
investigated[19]. 
Propensity score methods do have a few drawbacks for the naïve researcher.  Senn, 
Graff, and Caputo[21] contend that stratifying on the propensity score will produce an 
unbiased estimate of the treatment effect, but that it will have a greater variance than the 
OLS estimator in cases where linear regression is an appropriate model.  They also state 
that including covariates in the propensity score estimation which are irrelevant to 
treatment response increase the variance of the estimator as well[21].  This finding calls into 
question the idea that all covariates can be included indiscriminately in the propensity score 
estimation model and that we need not be worried about over-parameterization in that 
step of the propensity score analysis as argued by D’Agostino.  Senn, et al, admit that some 
knowledge is required on the part of the analyst as to whether covariates are known to 
have a stronger relationship with treatment assignment or with outcome, and if the former, 
then propensity score analysis can be useful, though knowledge is still required about which 
covariates should then be used to estimate the propensity score.  In any case, they conclude 
that “although popular, propensity score stratification is not to be considered as best 
practice among propensity score-based approaches”[21].  Becker and Ichino caution that, for 
matching within calipers, using small caliper widths will produce stronger matches, but at 
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the cost of total number of matched pairs, and also at the cost of generalizability of the 
results to the larger population[19]. 
Another issue for propensity score analyses is the presence of missing values for 
covariates that are used to estimate the propensity score.  Matching solves this problem, in 
a way, in that subjects with missing values can be excluded from matches.  The main 
downside is a reduced sample of matched pairs, as long as missing values are missing at 
random.  Also, clinical trials where subjects drop out before completion present a similar 
problem.  Solutions to these are areas of current research[16].   Lastly, if the propensity score 
is going to be used in a regression adjustment model, Rosenbaum and Rubin warn that 
“covariance adjustment cannot be relied upon to perform well unless the linear 
discriminant is highly correlated with the propensity score”[9].  This mirrors the previously 
mentioned warning issued by D’Agostino suggesting that covariance adjustment is not 
indicated if the treated and control groups have variances that differ greatly. 
Taking these various findings into consideration, this study will focus on the methods 











Before discussing the application of instrumental variables (IV) methods, it is helpful 
to explain two terms typically used in econometrics, endogeneity and exogeneity, which are 
central to the theoretical conception of IV analysis.  An endogenous variable refers to a 
variable that is correlated with the error term; the term endogenous means “determined 
within the system,”[14] and an ordinary least squares (OLS) regression using an endogenous 
explanatory variable will result in biased estimates since the explanatory variable and the 
error are related.  An exogenous variable is one that is not related to the error term.  The 
term exogenous means “determined outside the system.” A regression using an exogenous 
explanatory variable will capture only the effect that the explanatory variable has on the 
outcome, and the estimate of this effect will be free of bias. 
However, an unbiased estimate of the effect of an exogenous variable is still possible 
if an instrument (z) can be found[22].  It is important that changes in z be associated with 
changes in the endogenous variable (x), but that changes in z itself do not directly effect 
changes in the outcome (y), except via the indirect route of being associated with changes 




where u represents the error term.  Note that x and u are correlated, and thus OLS will 
produce biased estimates of the effect of x on y.  However, if we can find an instrument z 
which is related to x but not to the error term (i.e. z is exogenous), we can obtain an 
unbiased estimate of the effect of x on y[22].  This unbiased estimate is obtained by the two-
stage least squares (2SLS) method. 
To explain how 2SLS is carried out, I adapt the notation given by Brookhart, Rassen, 
and Schneeweiss for the two stages of regression[23]. 
 X = α0 + α1Z + α2C + ε1 (18) 
 Y = β0 + β1X + β2C + ε2. (19) 
Here, the treatment effect of treatment X is denoted in equation (19) by β1.  C is a vector of 
measured covariates, ε1 and ε2 are error terms, Z is an instrument, and Y is the outcome.  In 
order for  ̂1 to be an unbiased estimator in ordinary least squares, the treatment exposure 
must be uncorrelated with the error term ε2.  If treatment X and error ε2 are correlated, 
then the error term is capturing the effect of unobserved confounders and an OLS estimate 
of β1 will be biased proportional to the degree of that correlation.  Therefore, an instrument 
Z is found which isolates the effect of X on Y by virtue of being correlated with X but 
uncorrelated with ε2.  To do that, first estimate  ̂0,   ̂1,  and  ̂2 using OLS regression for 
equation (18) above.  This yields  ̂, which is plugged in to equation (19) in place of X to 
obtain  ̂1 using OLS.  This method is generalizable to multiple endogenous regressors, 
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where a separate first-stage regression is run to find each individual estimator  ̂i, where i = 
1,…,n for n different treatments, and each of these estimates is then plugged into the 
second stage equation for the outcome[23]. 
IV methods are also applicable to dichotomous treatments and instruments, where 
the IV estimator is known as the Wald estimator and is defined as follows[23]: 
 
     
 [ |   ]   [ |   ]
 [ |   ]   [ |   ]
  (20) 
Here Y is the outcome, X is the treatment, Z is the instrument, and   measures the 
treatment effect.  “The numerator of this estimator is the ITT [intention-to-treat] estimate – 
i.e., the effect of the instrument on the outcome measures as a risk difference.  The 
denominator is the difference in treatment rates between levels of the instruments…and is 
a measure of compliance”[23].  This estimator is more useful than the standard ITT estimator 
(which equals the numerator of the Wald estimator) when there is significant non-
compliance in the treatment groups, which causes bias towards the null in the ITT 
estimator[23]. 
There are two essential assumptions underlying the validity of a potential 
instrument.  The first is that the instrument is correlated with the explanatory variable; that 
is, Cov(Z, X) ≠ 0.  This assumption is essential because it is this relationship which allows us 
to use Z to determine the extent of the effect that X has on the outcome.  The second 
assumption is that the instrument is unrelated to the error term, i.e., Cov(Z, ε2) = 0.  This is 
fundamentally the most important aspect for a valid instrument, since this assumption is 
what allows for the unbiasedness of the resulting parameter estimates.  We cannot test the 
second assumption because we do not have an unbiased estimator of the true error 
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term[14], and therefore the selection of an instrument which satisfies the second assumption 
must be conducted on theoretical principles.  The first assumption can be easily tested 
based on the first stage regression of Z onto X in equation (18).  If  ̂1 = 0 then the 
assumption of instrument relevance is violated. 
Ideally, we would prefer to use OLS estimation of the treatment effect if possible, 
and only use IV analysis when we can be sure that our explanatory variables are 
endogenous and that this is producing significant bias in our estimates.  A way to test for 
endogeneity of the explanatory variables is the Wu-Hausman test[14].  Consider the 
following regression: 
                                 (21) 
where W represents an exogenous regressor which is not an instrument, and consider Z1i 
and Z2i as instruments for    .  To check whether an IV analysis is necessary, we can 
compare the OLS and 2SLS estimates and determine whether the difference between these 
estimates is significant.  If they differ significantly, we conclude that    is an endogenous 
variable and thus we should proceed with IV methods[14].  This is known as the Wu-
Hausman test, which is conducted in the following way.   
Estimate the first stage regression: 
                                         (22) 
We know that each instrument (Z) is uncorrelated with   , as are the exogenous regressors 
(W) by definition, and therefore     is uncorrelated with    only if    is uncorrelated with   .  
To test this, we run the following regression using OLS: 
                                 ̂        (23) 
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and test whether    = 0 using a standard t-test.  If we reject the null hypothesis we conclude 
that    is endogenous, since    and    will be correlated
[14].  Since OLS is preferable to IV 
methods unless strong endogeneity is present, we should conduct this test and proceed 
with an IV analysis only if indicated.   
If we have access to more instruments than endogenous variables, we can choose 
the best candidate and proceed, or we can use a linear combination of all IVs.  The second 
approach is optimal according to Zulehner[14].  Additionally, it is nice to have more IVs than 
endogenous explanatory variables because this situation allows us to test the validity of 
some of the instruments[14].  Consider the same regression with outcome    as shown 
above, where two potential instruments for X are Z1 and Z2.  Proceed to do an IV analysis 
using Z1 as the instrument for X, and compute the residuals  ̂.  Now, if Z2 is correlated with  ̂ 
then Z2 is not a valid instrument.  Under the null hypothesis that all IVs are uncorrelated 
with ε,    
     
  where n is the sample size,   
  is the coefficient of determination from the 
first-stage regression, and q is the number of instrumental variables from outside the model 
minus the total number of endogenous explanatory variables.  “If the test statistic exceeds 
the critical value we reject the null hypothesis and conclude that at least some of the IVs are 
not exogenous”[14].  This is known as the Sargan test.  We cannot know whether Z1 is valid, 
because we simply have to assume that it is uncorrelated with  ̂.  Thus we can never truly 
know whether our instruments are valid, since the validity of this test rests on the 
assumption that Z1 is indeed uncorrelated with the error term.  However, the test can still 
be useful because if both (or all) instruments were chosen using similar logic, the lack of 
validity of one of them ought to warn against the validity of the other(s) as well[14].  
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Likewise, if the test does not indicate that the extra instruments are invalid, it is at least 
some evidence of their validity as long as the theoretical reasoning for the exogeneity of Z1 
is solid.  In essence, this is a test that can confirm that an instrument or instruments may be 
invalid, though our only guide for assuming true validity is theoretical reasoning. 
The use of IV methods is fraught with difficulties and dangers.  Aside from the 
difficulty of identifying a potential instrument, we must be wary about candidates that have 
only a weak correlation with the explanatory variable to be instrumented, which in practice 
encompasses the majority of candidates, unfortunately.  These are called weak instruments.  
It is well recognized that using weak instruments is likely to produce estimates with large 
standard errors[24].  Additionally, weak instruments produce estimates that can be highly 
biased[14], which obviates the rationale for using IV analysis in the first place. 
While the practical difficulty of finding valid instruments is well known, due to the 
reliance on theoretical knowledge and expertise of the study subject matter; Bound, Jaeger, 
and Baker[24] also contend that the identification of suitable IVs may be more difficult than 
even traditionally thought, since even theoretically sound instruments can turn out to do a 
poor job.  They also warn “that even researchers working with very large data sets need to 
be more concerned about the finite-sample properties of IV estimators”[24].  These warnings 
were issued in their research on a well-known IV analysis conducted by Angrist and Kreuger 
in 1991.  Bound, et al, found that many of the findings reported in that seminal work may 
be dubious despite the use of very large sample sizes. 
Bound, et al, also detail another drawback to IV methods, which is that the 
parameter estimates are actually biased for finite sample sizes.  Denoting the IV parameter 
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estimate by  ̂iv, they say “ ̂iv is biased in the direction of the expectation of the OLS 
estimator of  .  The magnitude of this bias depends on both the sample size…and the 
multiple correlation between the instruments and the endogenous explanatory variable”[24].  
As such, even very large samples will produce biased estimates (though bias does reduce 
with sample size), and unless Z is perfectly correlated with X (which never happens), using Z 
to estimate  ̂ in the first stage regression introduces a bias that is inversely proportional to 
their degree of correlation.  The degree of bias of  ̂iv relative to  ̂ols can be estimated by 
1/F[24].  This fact can give a rough guide as to whether an IV analysis provides improved 
estimates as compared to traditional OLS, at least. 
Finally, Bound, Jaeger, and Baker report that the “common practice of adding 
interaction terms as excluded instruments” may increase the bias of IV parameter 









COMPARISONS OF CER METHODS AND SPINAL PROCEDURES 
In this section I will compare two competing spinal procedures: Bone morphogenetic 
proteins (BMP) versus autograft for degenerative disc disease, by using the four common 
statistical methods discussed previously.  Both procedures will be compared on the 
outcomes of length of stay, cost, and complications.  I give a brief description of these 
procedures and the importance of comparisons between them below, then give some 
recommendations as far as which CER analysis methods are optimal for conducting these 
comparisons, and draw final conclusions. 
A spinal autograft is a procedure in which a segment of bone is removed from a 
different section of the patient’s body (usually a rib or the iliac crest) and grafted to the 
spine in order to achieve spinal fusion.  Bone morphogenetic proteins are a family of growth 
factors that stimulate bone formation, and are a recent innovation (FDA approved in 2002) 
that represents an alternative treatment to autografts for spinal fusion.  Since autografts 
can have a number of drawbacks including morbidity, infection, and chronic pain at the site 
from which the graft bone was harvested; and may also be eliminated as an option for some 
patients, such as those requiring very large sections of bone for the graft or those who need 
repeat surgery and therefore do not have available bone for an autograft, BMP has become 
an important alternative, representing a quarter of all fusion procedures by 2006.  While 
BMP achieves higher success rates of spinal fusion, it has also been associated with an 
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increased risk of complications compared to iliac crest autografts.  Although BMP is more 
expensive initially, it is believed that the upfront cost may be more than offset via 
decreased utilization of health resources in the years after the operation.  Findings have 
been mixed.  This is the reason I will investigate this question. 
The data for these comparisons comes from MarketScan insurance claims data, 
which tracks inpatient and outpatient health resource utilization for claims from Medicare, 
Medicaid, and commercial insurance in the United States.  We have information for patient 
services rendered in the years 2000-2009.  The covariate measures include patient age, sex, 
Charlson comorbidity index (CCI), insurance type, and year of operation.  The outcome 
variables are length of hospital stay (LOS), cost, and complications.  ANCOVA and propensity 
score analyses were applied to compare the two procedures, and use of the county of 
residence as an instrumental variable for IV analysis was explored. 
Before analyzing the effectiveness of the various CER methods in reducing bias, we 
should know how the covariate balance looks between the groups without any adjustment.  
Table 1 shows the covariate breakdown between the BMP and autograft comparison 
groups.  Variables with means expressed as percentages represent the proportion of 








Table 1: Summary statistics for autograft and BMP patients 
 Autograft Patients (n=1308) BMP Patients (n=649) 
Mean SD 95% CI Mean SD 95% CI 
Age 57.34 13.34 (56.73, 58.18) 51.88 12.89 (50.88, 52.87) 
Sex (F) 61.31% -- (58.61, 63.96) 68.41% -- (64.68, 71.98) 
Year 2004.00 1.76 (2003.90, 2004.09) 2004.71 1.34 (2004.61, 2004.82) 
Charlson 0.19 0.54 (0.16, 0.22) 0.32 0.65 (0.27, 0.37) 
Commercial 63.30% --  (60.62, 65.92) 54.24% --  (50.32, 58.12) 
Medicaid 4.43% -- (3.38, 5.69) 36.06% -- (32.35, 39.88) 
Medicare 32.26% -- (29.73, 34.87) 9.71% -- (7.54, 12.25) 
LOS 4.62 10.55 (4.04, 5.19) 3.96 2.49 (3.76, 4.15) 
In-Hosp. Cost $30,354 29,919 (28,731, 31,977) $40,872 29,337 (38,611, 43,134) 
Outp. Cost $16,575 21,497 (15,409, 17,741) $19,873 19,395 (18,378, 21,368) 
Comp. Rate 13.61% -- (11.80, 15.59) 15.72% -- (13.00, 18.75) 
Total Comps. 0.11 0.41 (0.09, 0.13) 0.14 0.48 (0.10, 0.18) 
 
Confidence intervals for those variables were determined by the exact binomial method.  
The first seven variables are the covariate measures, and we can see from Table 1 that the 
BMP and autograft patients are not at all balanced on the covariates, as the confidence 
intervals for the covariate values do not overlap at all.  The last five variables are outcome 
measures, and we see that the two treatment groups differ significantly on two of the five 
outcomes if we don’t make any adjustments for covariate imbalance.  Since the two 
treatment groups differ significantly on every covariate measure, we should expect that 
standard ANOVA will produce biased estimates of the treatment effect of BMP versus 
autograft if performed on this dataset, as it does not adjust for the covariates.  Thus, 
statistical methods which adjust for covariate imbalance should be applied.  In section 5.1, 
the results for ANCOVA are presented, in section 5.2, propensity score based methods are 
presented, and in section 5.3, IV analysis using county of residence is explored.  
For the comparisons on individual outcome measures, I used one of two statistics to 
identify overly influential observations and remove them from the comparison.  For the 
length of stay outcome, visual inspection showed one obvious and extreme outlier, which 
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was confirmed by the DFBETAS statistic produced in SAS[25].  In short, this statistic measures 
the change in each parameter estimate, i.e., the β values in the regression, that results from 
the deletion of the observation in question.  For observation i, DFBETAS calculates 
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   (24) 
where    is the parameter estimate with observation i included,  ( )  is the parameter 
estimate with observation i deleted,  ( ) is the standard deviation of the estimate with 
observation i deleted, and (   )   is the (j, j)th element of ( 
  )  . 
For all other outcome measures, I determined overly influential observations by the 
DFFITS statistic, also produced in SAS.  “The DFFITS statistic is a scaled measure of the 
change in the predicted value for the th observation and is calculated by deleting the th 
observation”[25].  It is calculated 
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where  ̂  is the predicted outcome with observation i included,  ̂( ) is the predicted 
outcome with observation i deleted,  ( ) is the standard deviation of the estimate with 
observation i deleted, and  ( ) is the ith diagonal of the hat matrix with observation i 
deleted.  According to the SAS User’s Guide,  √  ⁄  is recommended as a cutoff value for 
identifying influential observations, where p is the number of parameters in the model, and 
n is the sample size used in fitting the model[25].  DFFITS with an absolute value greater than 





5.1 The ANCOVA Method 
5.1.1 Results for Length of Stay 
To examine the length of stay (LOS), it is assumed that LOS follows a Poisson 
distribution, and an ANCOVA model with log-link function was applied.  In the BMP versus 
autograft comparison group there were two extreme outliers for length of stay (74 and 367 
days).  With scaled DFBETA values and DFFITS values that were far, far removed from the 
values of all other observations, these were removed from the dataset due to their heavy 
influence on model fit[25], which left 1955 observations.  The results when including all 
covariates in the model and when including only the significant covariates in the model are 
shown in Table 2: 
Table 2: Full and final ANCOVA model for length of stay for BMP vs. autograft 
Full Model: Estimate SE P-value  Final Model: Estimate SE P-value 
Intercept 1.44 0.096 <.0001  Intercept 1.44 0.091 <.0001 
BMP -0.02 0.027 0.464     
AGE 0.003 0.001 0.009  AGE 0.003 0.001 0.007 
SEX (F) 0.03 0.023 0.204     
YEAR -0.03 0.007 <.0001  YEAR -0.03 0.007 <.0001 
CHARLSON 0.20 0.016 <.0001  CHARLSON 0.20 0.016 <.0001 
COMMERC. -0.16 0.035 <.0001  COMMERC. -0.16 0.035 <.0001 
MEDICAID -0.20 0.049 <.0001  MEDICAID -0.21 0.046 <.0001 
 
Here, and in all future references, the covariates are represented as follows:    is an 
indicator variable for the BMP procedure,    is a continuous variable for patient age in 
years,    is an indicator variable for patient sex is female,    is a continuous variable for the 
year of operation, where 2000 has been subtracted from the year in order to prevent this 
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variable from having an inordinate impact on the intercept terms in the models (since year 
of operation in this dataset ranged from 2001 to 2009, these years are represented simply 
by the numbers 1-9),    is a continuous variable for the Charlson comorbidity index,    is 
and indicator variable for commercial insurance, and    is an indicator variable for Medicaid 
insurance.  Thus, the final ANCOVA model for length of stay is the following: 
   (   )            (  )      (  )      (  )      (  )      (  )  
The BMP and sex variables were removed from the final model sequentially because 
they were not significant predictors of length of stay.  The interpretation of this model is as 
follows.  Consider the typical patient in this dataset: she is 56 years old, has the operation in 
2004, has a Charlson score of 0, and has commercial insurance.  This patient has an 
expected stay of 3.77 days.  Each 1-year increase in age increases expected length of stay by 
0.3%, each 1-year increase in year of operation decreases expected length of stay by 3.0%, 
each 1-point increase in the Charlson comorbidity score increases expected length of stay 
by 22.1%, commercial insurance decreases length of stay by 17.4% over Medicare 
insurance, and Medicaid decreases expected length of stay by 23.4% over Medicare 
insurance, when all else is held equal.  In this model, the BMP procedure is not significant, 
meaning there is no difference in expected length of stay between BMP and autograft 
patients. 
5.1.2 Results for In-Hospital Cost 
The second outcome variable for the comparison of spinal procedures is the cost of 
the procedure.  This cost is also broken down into initial in-hospital cost and 1-year follow-
up outpatient costs.  Since cost cannot be negative, a common practice is to log transform 
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the cost variable before fitting a linear model, because the transformed cost variable more 
closely follows a normal distribution.  I will first investigate inpatient costs.  This is a 
measure of payments made to the hospital and the principal physician for the inpatient 
admission associated with the procedure.  There were 62 outliers for inpatient cost in the 
dataset, with 14 autograft and 48 BMP patients removed, due to DFFITS statistics with 
absolute values greater than  √  ⁄ , which is 0.1196 for this sample.  The ANCOVA 
approach yields the following model for inpatient cost: 
Table 3: Full and final model for inpatient cost for BMP vs. autograft 
Full Model: Estimate SE P-value  Final Model: Estimate SE P-value 
Intercept 9.42 0.188 <.0001  Intercept 9.40 0.045 <.0001 
BMP  0.46 0.054 <.0001  BMP 0.45 0.053 <.0001 
AGE 0.0007 0.002 0.763     
SEX (F) 0.009 0.047 0.851     
YEAR -0.02 0.014 0.094     
CHARLSON 0.06 0.042 0.126     
COMMERC. 0.84 0.073 <.0001  COMMERC. 0.82 0.053 <.0001 
MEDICAID  -0.16 0.106 0.130  MEDICAID -0.17 0.085 0.046 
 
   (            )           (  )      (  )      (  ) 
Sex, age, Charlson, and year of operation variables were removed sequentially from 
the model due to lack of significance at the α=0.05 level, though Charlson and year were 
close to this cutoff.  Once taking covariates into account, the BMP procedure is more 
expensive than autograft in initial cost by 56.83%, which aligns with the results of previous 
findings as well as theory.  For a patient with commercial insurance, BMP would cost 
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$43,045 for the procedure and associated inpatient stay, while autograft would cost only 
$27,447 according to this model. 
5.1.3 Results for 1-Year Follow-up Outpatient Cost 
 
Of the 1957 patients to receive either the BMP or autograft procedure in our 
dataset, 1815 of them combined for 347,030 total outpatient services for which they were 
billed in the one-year period following their operations, while 142 did not incur outpatient 
costs at all over the 1-year follow-up period.  These 142 patients would all be regarded as 
influential observations by the DFFITS statistic, but I have not removed them.  Therefore, all 
1957 patients remained in the sample, and the ANCOVA method yields:  
Table 4: Full and final model for 1-year outpatient cost for BMP vs. autograft 
Full Model: Estimate SE P-value  Final Model: Estimate SE P-value 
Intercept 7.14 0.793 <.0001  Intercept 6.70 0.750 <.0001 
BMP  0.57 0.234 0.015  BMP 0.58 0.231 0.012 
AGE 0.02 0.010 0.066  AGE 0.02 0.010 0.026 
SEX (F) 0.25 0.205 0.214     
YEAR -0.04 0.059 0.479     
CHARLSON 0.28 0.173 0.106     
COMMERC.  -0.14 0.318 0.658  COMMERC. -0.11 0.317 0.724 
MEDICAID  0.97 0.433 0.025  MEDICAID 1.09 0.427 0.011 
 
   (               )           (  )      (  )      (  )      (  ) 
 
The ANCOVA model shows that the BMP procedure is more expensive than 
autograft for 1-year outpatient costs as well, countering the theory and previous findings 
that BMP is less expensive in terms of follow-up care.  However, due to the possibility of 
patients requiring re-operations, it is possible that the BMP procedure will be less expensive 
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in total cost over longer follow-up timeframes compared to autograft if autograft patients 
have a higher rate of requiring re-operations, since re-operations would not show up in 
initial cost or in outpatient costs. 
5.1.4 Results for Complication Rate 
Complications were measured over 30 days and 90 days, and in terms of rate of 
complications and total number of complications.  I will examine the 30-day and 90-day rate 
of complications for BMP versus autograft patients using logistic regression since the 
outcome is binary.  ANCOVA produces the following full and final models: 
Table 5: Full and final model for 30-day complication rate for BMP vs. autograft 
Full Model: Estimate SE P-value  Final Model: Estimate SE P-value 
Intercept -2.84 0.450 <.0001  Intercept -2.65 0.296 <.0001 
BMP 0.04 0.079 0.649     
AGE 0.02 0.007 0.018  AGE 0.01 0.005 0.013 
SEX (F) -0.01 0.069 0.875     
YEAR 0.003 0.041 0.941     
CHARLSON 0.46 0.094 <.0001  CHARLSON 0.50 0.091 <.0001 
COMMERC. -0.07 0.101 0.484     
MEDICAID 0.22 0.144 0.134     
 
   [  (                   )]            (  )      (  ), 
This model indicates that each 1-unit increase in a patient’s age increases the chance 
of complications by 1%, and each 1-unit increase in the Charlson score increases the chance 
of complications by 64.87% within the 30 day timeframe, for fixed values of the other 
variable.  For example, a 56 year old patient with a Charlson score of 0 has a 12.37% chance 
of experiencing complications within 30 days, according to the model, while a 56 year old 
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patient with a Charlson score of 1 has 20.39% chance of experiencing complications, which 
is nearly 65% greater than the chances of a patient with a Charlson score of 0.  The BMP 
indicator is not a significant estimator of complication rate in the full model, which suggests 
that BMP and autograft patients do not differ in 30-day rate of complications. 
The rate of complications over a 90-day follow-up period shows nearly identical 
results to the 30-day period.  The procedure variable is not significant in either timeframe, 
and only age and Charlson score are significant in the ANCOVA model, with identical 
parameter estimates and a slightly different intercept.  Again, the conclusion is that BMP 
patients do not differ from autograft patients in the rate of complications over 90 days post 
surgery. 
5.1.5 Results for Total Number of Complications 
 
Though the BMP and autograft treatment groups do not differ in the rate of 
complications post surgery, perhaps they do differ in the total number of complications 
they experience.  We were able to extract information for the following types of post-
surgery complications: renal, cardiac, neurological, deep vein thrombosis or pulmonary 
embolism, pulmonary complications, infection, or wound complications.  This means that 
any given patient could experience a maximum of 7 different complications as a result of 
the procedure.  Since complications are a count variable, I assume an underlying Poisson 
distribution and use a log-link function in a general linear model.  In the 30-day follow-up 




Table 6: Full and final model for total number of complications for BMP vs. autograft 
Full Model: Estimate SE P-value  Final Model: Estimate SE P-value 
Intercept -3.41 0.548 <.0001  Intercept -2.66 0.189 <.0001 
BMP 0.07 0.157 0.647     
AGE 0.01 0.007 0.110     
SEX (F) 0.02 0.141 0.887     
YEAR 0.06 0.040 0.131  YEAR 0.08 0.038 0.047 
CHARLSON 0.50 0.066 <.0001  CHARLSON 0.54 0.061 <.0001 
COMMERC. 0.18 0.213 0.389     
MEDICAID 0.33 0.268 0.224     
 
   (           )            (  )      (  ) 
 
This model suggests that only a patient’s Charlson comorbidity index and the year of 
operation significantly  affect the total number of complications in the 30 days post surgery.  
Age was nearly significant, but not at the α=0.05 level.  Interestingly, this model suggests 
that procedures performed in more recent years have higher numbers of complications 
over a 30-day follow-up than procedures performed in the earlier years of the sample. 
The 90-day follow-up period again provides very similar results.  The same variables 
are significant for the final model as they were for the 30-day follow-up, and the parameter 
estimates are also very similar.  All the findings mentioned for complication rate and total 
number of complications suggest it doesn’t matter whether a 30-day or a 90-day follow-up 






5.2 Matching on the Estimated Propensity Scores 
 
Recall that BMP versus autograft patients were significantly different on all five 
measured covariates in the study: age, sex, year of operation, Charlson comorbidity score, 
and insurance type.  Before examining the results of propensity score methods, let’s first 
examine the extent to which propensity score matching is useful in reducing imbalance on 
the measured covariates in the dataset.  I conducted an optimal one-to-one matching of 
BMP patients with autograft patients using the vmatch macro[26] from the Mayo Clinic.  
According to its authors, “The vmatch macro matches each of N cases with a minimum of 
"a" controls to a maximum of "b" controls from a total pool of M controls.  The vmatch 
macro uses the case-control "distance matrix" as input. This matrix has one row per case 
and one column per potential control.  Each cell entry is the distance, Dij, between the i-th 
case and the j-th potential control.  Output includes the assignments of cases to controls 
and summaries of the matching efficacy”[26].  vmatch requires the use of the nobs macro[27] 
and the dist macro[28] in order to run.  Using a caliper distance of 1/5 the standard deviation 
of the estimated propensity scores as recommended by Austin[18], optimal one-to-one 
matching resulted in 463 of the 649 BMP patients being matched to autograft patients as 
controls.  The covariate breakdown after matching is described in the Table 7 below. 
Table 7: BMP vs. autograft covariate balance after matching on propensity score 
 Autograft Patients (n=463) BMP Patients (n=463) 
Mean SD 95% CI Mean SD 95% CI 
Age 54.33 11.63 (53.27, 55.39) 53.32 12.34 (52.20, 54.45) 
Sex (F) 64.36% -- (59.81, 68.73) 66.31% -- (61.80, 70.60) 
Year 2004.65 1.30 (2004.53, 2004.77) 2004.63 1.25 (2004.52, 2004.75) 
Charlson 0.23 0.55 (0.18, 0.28) 0.26 0.60 (0.20, 0.31) 
Commercial 75.81% -- (71.64, 79.64) 76.03% -- (71.87, 79.85) 
Medicaid 10.58% -- (7.93, 13.75) 10.37% -- (7.74, 13.51) 
Medicare 13.61% -- (10.62, 17.07) 13.61% -- (10.62, 17.07) 
 41 
 
When comparing to the covariate breakdown given at the beginning of section 5, we 
can see that one-to-one matching on the propensity score has eliminated nearly all of the 
imbalance in observed covariates between the two groups.  There is a great deal of overlap 
in the confidence intervals for all of the observed covariates now, whereas before matching 
on the propensity score there was no overlap in any of them. 
Heeding the argument by Austin[18] that matched pairs should not be considered 
independent, comparisons between the two treatment groups will be conducted using a 
paired t-test for continuous outcome variables or McNemar’s test for dichotomous 
outcome variables. 
Results for Matching on the Estimated Propensity Scores 
Table 8 summarizes the results of matched pair analysis based on the estimated 
propensity scores for all of the outcome variables of interest. 
Table 8: Results for all outcomes based on matched samples 
 
Autograft Patients BMP Patients 
P-value 
for Diff 
in Means Mean SE Mean SE 
Length of Stay 4.74 17.00 3.98 2.56 0.332 
In-Hospital Cost 35,809 30,401 43,505 28,217 <.0001 
1-Year Outp. Cost 21,132 29,157 19,947 19,061 0.432 
30-Day Comp. Rate 13.17% -- 14.69% -- 0.518 
90-Day Comp. Rate 13.61% -- 16.41% -- 0.245 
30-Day Total Comps. 0.11 0.38 0.13 0.46 0.593 
90-Day Total Comps. 0.12 0.39 0.14 0.47 0.457 
 
For the length of stay outcome, a paired t-test shows that the difference in means is 
0.77 days, with BMP having the shorter average stay, with a 95% confidence interval of       
(-0.78, 2.32).  It is of note that the autograft patient with an in-hospital length of stay of 367 
days was matched to a BMP patient based on their covariate measures, and virtually the 
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entire difference in means is due to that one extreme outlier.  If this patient had not been 
matched, the 462 other matched pairs would have combined for 1835 total days among 
BMP patients and 1831 total days among autograft patients, which would make the 
difference in their means virtually zero.  Even with this observation in the sample, the 
difference in means is not significant. 
The ANCOVA method showed that the BMP procedure is not a significant predictor 
of length of stay.  The propensity score matching method mirrored that finding, and 
excluding the outlier patient, the difference in means from the paired t-test followed a 
normal distribution extremely closely, which is the primary assumption for the validity of 
the paired t-test. 
For in-hospital cost, a paired t-test shows the difference in mean in-hospital cost to 
be $7,697, with autograft patients having a lower mean cost, with a 95% confidence interval 
of (3,941, 11,452), so the result is significant.  The difference in means approximates a 
normal distribution rather well.  Again, this agrees with the ANCOVA result that showed the 
BMP procedure to be a significant factor in in-hospital cost. 
The difference in mean 1-year outpatient cost post surgery is $1,185, with BMP 
patients having a lower mean cost, and a 95% confidence interval of (-1,776, 4,146), 
meaning the result is not significant.  This is in stark contrast to the results obtained via the 
ANCOVA method, which had BMP patients with a significantly higher outpatient cost over a 
1-year follow-up period post surgery. 
For 30-day complication rate, McNemar’s test returns a statistic value of 0.4188, 
which from a chi-square distribution with 1 degree of freedom, has a p-value of 0.52 for 
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values this extreme or more extreme.  Thus, BMP does not differ significantly from 
autograft in 30-day complication rate.  This can also be seen from the odds ratio of 1.13 for 
autograft versus BMP patients, with a 95% confidence interval of (0.78, 1.65).  These 
findings match the ANCOVA results that show that BMP does not differ significantly from 
autograft in 30-day complication rate. 
As before, similar results are found for the 90-day complication rate.  McNemar’s 
test returns a statistic value of 1.35.  From a chi-square distribution with 1 degree of 
freedom, this has a p-value of 0.24 for values this extreme or more extreme.  The odds ratio 
for autograft versus BMP patients is 1.25, with a 95% confidence interval of (0.87, 1.79), and 
thus BMP does not significantly differ from autograft in 90-day complication rate. 
The mean difference in total number of complications for 30-day follow-up is 0.015, 
with autograft patients having fewer complications on average, with a 95% confidence 
interval of     (-0.04, 0.07).  Thus, there is not a significant difference in total complications 
30 days post surgery between BMP and autograft patients.  The mean difference in this case 
follows a normal distribution with very small variance. 
The 90-day follow-up period shows similar results: the mean difference in total 
complications is 0.022 with autograft patients having fewer complications, with a 95% 
confidence interval of       (-0.04, 0.08).  Again, the mean difference follows a normal 
distribution with small variance. 
5.3 Using Propensity Score as a Covariate in Regression 
 
This method is analogous to the ANCOVA method presented in section 5.1, but now 
the estimated propensity score replaces the vector of the five individual covariates in the 
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regression model.  As before, outliers were removed based on DFBETAS or DFFITS statistics 
before running the regressions. 
5.3.1 Results for Length of Stay 
Two outliers were removed as their DFBETAS statistics values were more than 
double any of the other observations in the sample, leaving 1955 patients in the 
comparison.  The model shows that the propensity score is highly significant (p-value < 
.0001) but the BMP procedure indicator variable is not significant (p-value = 0.45).  Thus we 
would conclude that covariate measures do affect length of stay but that BMP does not 
differ from autograft in expected length of stay.  This result is in agreement with both the 
ANCOVA method and the method of matching on the propensity score. 
5.3.2 Results for In-Hospital Cost 
76 outliers for in-hospital cost were removed due to a DFFITS statistic with an 
absolute value greater than 0.0639, leaving 1881 patients in the sample.  The model shows 
that the BMP variable is highly significant (p-value < .0001), and that the expected cost for 
BMP patients is 53.72% more than for autograft.  The propensity score was not significant in 
this model, indicating that the covariates do not significantly influence inpatient cost.  
Again, this matches the results of both the ANCOVA and the propensity score matching 
methods suggesting that BMP does differ from autograft significantly in in-hospital cost, 
with BMP being more expensive. 
5.3.3 Results for 1-Year Follow-up Outpatient Cost 
For outpatient cost, as with ANCOVA, there were 142 patients with no outpatient 
costs at all over the 1-year follow-up, and all would have been labeled outliers by the DFFITS 
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statistic, but I did not remove them.  As a result, all 1957 patients remained in the sample.  
The model shows that both BMP (p-value = 0.01) and the propensity score (p-value = 0.03) 
have a significant effect on outpatient cost, with BMP patients having expected costs 78% 
greater than autograft patients.  This finding is in agreement with the ANCOVA results, but 
in stark contrast to the propensity score matching method, which found no effect for BMP 
versus autograft on 1-year outpatient cost. 
5.3.4 Results for Complication Rate 
For the 30-day complication rate, neither BMP nor the propensity score is a 
significant predictor of development of complications post surgery.  This is also true for the 
90-day complication rate.  Both of these findings are in agreement with the ANCOVA and 
propensity score matching methods which suggest that BMP does not differ significantly 
from autograft in rate of complications. 
5.3.5 Results for Total Number of Complications 
For the total number of complications 30 days post surgery, BMP is not a significant 
predictor of the number of complications, but the propensity score is (p-value = 0.007).  The 
90-day total number of complications has the same results.  ANCOVA and propensity score 
matching methods also showed that BMP does not differ significantly from autograft in 
terms of the total number of complications. 
5.4 Instrumental Variables Method 
In previous exploratory analyses on this dataset, it was determined that patient 
county of employment is the only potentially suitable instrumental variable.  Many other 
variables from the dataset were investigated, but ruled out.  By way of example, physician 
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ID and hospital location are two variables that are commonly considered as potential IVs in 
medical observational studies; however, they are unsuitable for this study because in this 
dataset they have missing values, and the values are not missing at random.  As such, using 
them as IVs would introduce bias.  Therefore, this section will focus on the suitability of 
county of employment as an IV for the outcomes being studied. 
5.4.1 Testing for Endogeneity of the BMP Procedure Variable 
Recall that unless the explanatory variable is indeed correlated with the error term, 
we would prefer to use OLS estimation.  Thus, the first step when considering an IV 
approach is to test this condition with the Wu-Hausman test.  However, the Wu-Hausman 
test itself relies upon OLS, and is not fit to handle many-leveled categorical variables for 
either the potentially endogenous regressor or for the IV which will be used in its place.  If 
both the endogenous variable and the instrument are binary, we have the Wald estimator 
and we can proceed.  If only the endogenous variable is categorical with many levels, 
Lochner and Moretti[29] have proposed a distinct test of exogeneity.  But the case where the 
potential instrument is a many-leveled categorical variable requires further study.  Some 
researchers proceed with the Wu-Hausman test even when either the endogenous or 
instrumental variable is categorical (usually binary), but this is technically not the proper 
purview of the Wu-Hausman test. 
The difficulty of empirically determining the endogeneity of the BMP variable in this 
case is probably an argument against proceeding with an IV analysis, unless there is a strong 
theoretical reason to believe that the BMP procedure variable is endogenous.  If it is not, IV 
 47 
 
analysis is certain to be far more detrimental than helpful, given the results to be presented 
in the next section. 
5.4.2 Testing Instrument Relevance 
 Since both BMP and employee county are categorical variables, we cannot take a 
measure of correlation, but there are a number of options for assessing the degree of 
association between these variables.  Since the relationship between BMP and employee 
county cannot naturally be classified in terms of one variable “explaining” the other, I prefer 
to measure association between them with a reduction in error approach.  In short, this 
approach attempts to measure how much knowledge one variable gives us in trying to 
predict the value of another variable.  Symmetric λ is one statistic which uses this approach.  
This statistic is calculated by  
 
  
∑    ∑         
      
   (26) 
Consider a 2xJ contingency table with BMP procedure status composing the rows i = 1, 2, 
and employee county values composing the columns j = 1,…,J, and     is the observed count 
in the cell for row i and column j.  Then 
        (   ),  
       (   ),  
      (   ),  
      (   )
[30]. 
Symmetric λ will have values between 0 and 1, and it represents the reduction in error rate 
a prognosticator would experience by having knowledge of one variable in trying to predict 
the other variable.  If the variables have no association whatsoever, a prognosticator will 
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not see any reduction in the error rate of his guesses, and λ = 0.  Perfect association 
between the variables gives λ = 1, since the prognosticator would see 100% reduction in his 
rate of errors by knowing the value of one variable before trying to predict the value of the 
other[31]. 
 The symmetric lambda statistic value for association between BMP and employee 
county is 0.09 with a 95% confidence interval of (0.08, 0.11).  Knowing the value of BMP 
would reduce errors in guessing employee county (or vice versa) by about 9.4% over 
guessing without this knowledge.  This is a significant result, meaning that employee county 
passes the assumption of instrument relevance, though it would likely be considered a weak 
instrument, since this level of association is not particularly strong.  As mentioned, it is rare 
in practice for instruments to be very strong, but with a sample of only 1663 (since 
employee county is missing for 294 patients in the dataset), the weakness of this instrument 
raises quite a red flag about proceeding with an IV analysis.  Bound, Jaeger, and Baker cast 
doubt upon the findings of a classic Angrist and Kreuger study (1991) in part due to using a 
weak instrument, and their sample size exceeded 300,000[24].  Recall that the bias of an IV 
estimate is indirectly proportional to its correlation with the endogenous variable.  They 
also warn that if the instrument is only weakly correlated with the endogenous variable, this 
can greatly exacerbate the problems that are created if the instrument is actually correlated 
with the error term as well[24].   
5.4.3 Hypothesizing Instrument Exogeneity 
As mentioned in section 4 of this study, the exogeneity of a chosen instrument cannot be 
tested empirically, as we do not have an unbiased estimate of the true error.  The 
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exogeneity of the instrument must therefore be assumed to be true based on theoretical 
grounds.  It seems reasonable to assume that a patient’s county of employment would have 
no effect whatsoever on his response to either the BMP or autograft procedure, and thus it 
seems reasonable to assume that county of employment is exogenous.  We must keep in 
mind though, that even a very slight correlation between employee county and the error 
term would create highly biased estimates of the treatment effect, due to the instrument’s 
weak correlation with the BMP procedure variable discussed above[24]. 
5.5 Recommendations 
Because each outcome variable represents an independent analysis, I will address 
each outcome individually.  For the length of stay, regression and matching assumptions are 
all satisfied, and all three methods agreed, so choice of method is simply a matter of 
preference. 
For in-hospital cost, the final model contains only categorical predictors in the 
ANCOVA method, so linearity of the relationship is not a concern.  The error appears more 
or less normally distributed (see Figure 1 Panel A) and with constant variance (see Figure 1 
Panel B), though the model fits more poorly in the region of patients with very low inpatient 
cost (see Figure 2).  If the dataset were smaller, ANCOVA may be preferable to PS matching 
if matching resulted in only a small number of pairs.  Overall, ANCOVA appears valid here, 
and all three methods produced the same conclusions.  PS matching also appears valid here, 




For 1-year outpatient cost, we had the odd circumstance of 142 of the 1957 patients 
having no outpatient costs in the 1-year follow-up, which I chose not to discard.  A 
researcher could choose to simply discard all of these observations and proceed with 
ANCOVA or PS regression.  However, the sample was composed of 67% autograft patients, 
yet autograft patients accounted for 79% of the zero outpatient cost observations.  To 
throw these observations out is to discard pertinent information, in my opinion – autograft 
patients are more likely to avoid outpatient costs post surgery.  If these observations 
remain in the sample, ANCOVA assumptions are violated (see Figure 3).  Thus, if a 
researcher deems the outlier observations to contain pertinent information, he should 
proceed with the PS matching method, or another method which does not make 
assumptions about linearity or about normality of the error term.  Unsurprisingly, ANCOVA 
and PS regression produced the same conclusion – that BMP differed significantly from 
autograft – but PS matching produced an entirely different result.  The PS matching result is 
far more likely to be valid.  Considering that the zero counts produced some outliers for the 
difference in cost, the difference still follows a normal distribution reasonably well. 
For complication rate, model assumptions for ANCOVA methods appear to be 
satisfied.  In the matched pairs design there were no sparse cell counts, so McNemar’s test 
is valid here as well, allowing for PS matching.  All three methods agreed with each other. 
For total number of complications, linearity of relationship, normality of error, and 
constancy of error variance appear to be satisfied (see Figure 4 Panel A).  However, the 
error term does not appear to be independent of the predictor (see Figure 4 Panel B).  As a 
result, ANCOVA assumptions are violated.  The difference in means of matched pairs follows 
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a normal distribution (with large variance), so PS matching is valid.  The results of all three 











ANCOVA has its drawbacks, which is why propensity scores, IV methods, and 
numerous other methods have been developed in the first place.  Primarily, ANCOVA 
produces biased estimates of the treatment effect when important covariates are omitted 
from the model.  This is where IV methods find their application.  Secondly, covariate 
adjustment is ineffectual when the covariates are so numerous that multiple experimental 
units (from each of the treatment assignments) cannot be found with the same covariate 
measures.  This is where propensity score methods are useful.  Also, as mentioned, 
ANCOVA depends on proper specification of the regression relationship, but this is true of 
all statistical models, with varying degrees of severity when this condition is violated. 
Propensity score analyses do have drawbacks.  For example, Senn, Graf, and 
Caputo[21] find that stratifying on the propensity score will produce estimates with greater 
variance than least squares regression under the circumstances where both methods are 
unbiased, indicating that propensity score analyses should not be used simply for 
convenience or simplicity’s sake, but only when there is strong risk of bias due to 
confounding.  They also warn that including covariates irrelevant to the response (which 
researchers may wish to do if the covariates are believed to be related to assignment) 
reduces efficiency further.  That is to say, the exemption from over-parameterization does 
not come without a cost.  Winkelmayer and Kurth[32] caution that “even though [propensity 
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scores] can balance observed baseline covariates between exposure groups, they do 
nothing to balance unmeasured characteristics and confounders,” (which is the role of the 
instrumental variables method).  “Secondly, one cannot use covariates that may be affected 
by the exposure of interest in the model that estimates the PS.”  This indicates a need for 
some theoretical expertise about which covariates could be potentially troublesome if 
included in a model estimating the propensity scores. 
The drawbacks to IV analysis are rather severe.  First, the selection of a suitable 
instrument is a difficult task that relies heavily on theoretical reasoning, and the suitability 
of an instrument is difficult or impossible to test empirically.  Even instruments that seem 
highly intuitive candidates can be fatally flawed in reality.  Second, as stated by Brookhart, 
Rassen, and Schneeweiss[23], even when valid, “IV methods are inefficient and should not be 
used as a primary analysis unless unmeasured confounding is thought to be strong.”  Both 
of these drawbacks highlight the strong level of theoretical expertise required to even 
consider using IV methods, first simply for the recognition of the need for IV methods and 
second for the identification of potential instruments.  Third, IV analysis is consistent only in 
large samples. 
Because IV analysis is useful (superior to OLS) only when unmeasured confounding is 
strong, and is also highly sensitive to the validity of the chosen instrument(s) along with 
other drawbacks, it behooves the researcher to use IV analysis only when necessary.  The 
Wu-Hausman test is one method for determining whether the treatment is correlated with 
the error term by comparing OLS estimates to 2SLS estimates.  If we have more instruments 
than we do treatment effects to estimate, we can use the Sargan test to check whether any 
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of the “excess” instruments are exogenous (unrelated to the error term), though this test 
requires some strong assumptions[14].  Additionally, further research is needed for situations 
where the potential instrument is a many-leveled non-ordinal categorical variable. 
Unless confounding is thought to be strong due to unmeasured covariates, or the 
sample size is small, propensity score matching seems to be the safest choice for dealing 
with covariate imbalance between treatment groups.  Its assumptions are easily tested, and 
its drawbacks are rather mild.  ANCOVA and propensity score regression techniques have 
stricter assumptions and some not so easily tested, though they may be preferable if the 
sample size is small and only few matched pairs can be created by matching techniques.  IV 
methods should only be used when there is strong suspicion of endogeneity of explanatory 
variables, and then only provided that a valid instrument can be found.  It requires very 
strong assumptions which may not be empirically testable at all.  The drawbacks to this 
method are too severe for use in situations where it is not absolutely imperative to 
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Figure 1: Panel A shows that the error term is approximately normally distributed for the 
ANCOVA model for the in-hospital cost outcome variable, and Panel B shows that the error 
term does not show a pattern which would indicate that error variance is non-constant.  












Figure 2: The Q-Q plot shows that the model fits poorly in the region where in-hospital cost 
is low, as the residuals in that region are much larger than expected in absolute value.  The 
same issue can be seen in Figure 1 Panel A, where the left tail of the distribution of residuals 













Figure 3: This graph shows that the error term is not normally distributed for the ANCOVA 
model of outpatient cost if zero-cost patients are not removed from the sample.  If a 
researcher wishes to proceed with an analysis that includes these patients, he should not 











Figure 4 Panel A                                                                                     
        
 
Figure 4 Panel B  
    
Figure 4: Panel A shows that total number of complications appears to follow a linear 
relationship with its predictors.  Panel B shows that the error term does not appear to be 




SAS Code:  This section contains some example SAS code for conducting the 
ANCOVA and propensity score methods discussed in the paper, as well as SAS code for 
determining the symmetric lambda statistic used to test instrument relevance for the IV 
method.   
To run ANCOVA for length of stay: 
Proc GenMod data=BMP_Auto4 plots=all; 
 Class Sex Insurance BMP; 
Model Days = BMP Age Sex Year2 Charlson Insurance  
/ dist=poi link=log type3; 
run; 
The “GENMOD” procedure runs generalized linear models in SAS; the “class” statement lists 
the variables in the model which are categorical; BMP, Age, Sex, etc. are the explanatory 
variables in the model; the “dist” option allows you specify the distribution for the response 
variable (“poi” for Poisson); and “link” option allows you to specify the link function for that 
distribution (“log” for the standard log-link function).  This code gives the full model for 
length of stay; to get the reduced model, explanatory variables were removed sequentially 
based on the p-value.   
 To get the estimated propensity scores for the BMP and autograft patients: 
Proc logistic data=Dataset.BMP_Auto; 
 Class BMP Sex Insurance; 
 Model BMP (event='1') = Age Sex Year Insurance Charlson  
/ selection = stepwise; 
 Output out=EstPropensity Pred=PropScore; 
run; 
The “LOGISTIC” procedure runs a logit model by default.  The “selection” option allows you 
to choose the variable selection method for the final model.  The “output” statement writes 
a new SAS dataset which contains whichever variables from the logistic regression that you 
tell SAS to write – I have told SAS to write the variable for the predicted probability with the 
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“Pred=” option, and named that variable PropScore.  I can then use this variable PropScore 
to do propensity score regression, illustrated in the following code: 
Proc GenMod data=PSLOS plots=all; 
 Class BMP; 
 Model Days = BMP PropScore / dist=poi link=log type3; 
run; 
This code is identical to the ANCOVA code above, except that PropScore replaces the vector 
of covariates which were each listed individually in the ANCOVA model after BMP. 
For the continuous outcomes in the propensity score matched sample, the paired t-
test is conducted by: 
Proc ttest data=Dataset.PSMatchedLOS; 
 paired BMPLOS*AutoLOS; 
run; 
The “TTEST” procedure conducts Student’s t-test.  The “paired” statement indicates that it 
is a matched-pairs design (not independent).  The two outcomes to be compared (BMP 
length of stay with autograft length of stay) are joined with an asterisk. 
To get the symmetric λ statistic for measuring association between categorical 
variables which are not necessarily explanatory: 
Proc freq data=Dataset.BMP_Auto; 
 tables BMP*EmpCty / measures cl; 
run; 
The “tables” statement creates the contingency table between the variables for which you 
wish to measure association (BMP and employee county in this case), the “measures” 
option provides a number of statistics that measure association, and the “cl” option 
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